The White House withdrew its nomination of Heidi Overton to lead the Food and Drug Administration (FDA) on Tuesday evening amid mounting skepticism about her chances of Senate confirmation, according to multiple sources familiar with the decision. Overton had been scheduled for a vote before the Senate Health, Education, Labor and Pensions Committee on Wednesday, a critical step toward her potential confirmation as FDA commissioner.

Overton, a physician certified in public health and preventive medicine, has served as the deputy director of the White House Domestic Policy Council and was deeply involved in former President Donald Trump’s health policy initiatives. Trump nominated her in August to head the agency responsible for regulating drugs, vaccines, tobacco, and most of the U.S. food supply. The position has been vacant since May, when former commissioner Marty Makary resigned amid disagreements with White House officials over policies including fruit-flavored vaping products.

The nomination faced resistance from multiple quarters. Some Democratic senators opposed her candidacy, while prominent figures within the Make America Healthy Again (MAHA) movement, allied with former Health Secretary Robert F. Kennedy Jr., also expressed doubts about her commitment to challenging corporate interests. Concerns from Republican senators further complicated her path, with particular scrutiny over her stances on vaping products, abortion medications, and vaccine policies.

Senator Bill Cassidy (R-Louisiana), chairman of the Senate health committee, stated he believed there was a "viable confirmation path" for Overton. Cassidy, a physician who previously supported Kennedy’s confirmation but has since clashed with him on vaccine issues, said on Tuesday that discussions with Overton had alleviated many of his concerns and that she would adhere to scientific guidance in her role. However, he acknowledged remaining reservations from antiabortion senators seeking additional assurances from the administration.

In previous comments, Cassidy had expressed “strong concerns” about her nomination, particularly highlighting her involvement in an executive order aiming to reduce and space out childhood vaccinations, which he found unsettling. During her confirmation hearing, Overton affirmed the safety and efficacy of combined vaccines such as the measles, mumps, and rubella (MMR) shot, a stance that contrasts with vaccine skepticism expressed by Trump during his tenure.

Some MAHA activists criticized Overton for her perceived lack of opposition to regulatory decisions favoring corporate interests. Accusations included her role in supporting increased production of the herbicide glyphosate, as well as her participation in easing restrictions on fruit-flavored vapes. White House officials disputed these claims, stating Overton’s role was primarily legal review rather than policy advocacy.

Activists opposing her nomination launched a public campaign in recent days, portraying Overton as aligned with the vaping industry and urging senators to reject her. The group behind the effort, Health in Office, described itself as nonpartisan and concerned about the direction of Trump's health policy priorities.

With the withdrawal of Overton’s nomination and Democrats poised to control Congress following the recent midterm elections, it is unlikely that Trump’s administration will secure a permanent FDA commissioner before leaving office. Kyle Diamantas, the agency’s current acting chief and former senior counselor to Kennedy, continues to oversee the FDA in the interim.